Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40005417
Localisation
United States of America
Northern America
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
10/07/2025
Statut
Classification
1.5°C
Année cible
2030
Statut
Targets set
Classification
1.5°C
Année cible
2045
Overall Net-Zero Target: Merck & Co., Inc., Rahway, New Jersey, U.S.A., which is known as MSD outside the U.S. and Canada commits to reach net-zero greenhouse gas emissions across the value chain by 2045. Near-Term Targets: Merck & Co., Inc., Rahway, NJ, U.S.A., which is known as MSD outside the U.S. and Canada commits to reduce absolute scope 1 and 2 GHG emissions 46.2% by 2030 from a 2019 base year.* Merck & Co., Inc., also commits to reduce absolute scope 3 GHG emissions 30% within the same timeframe.* *The target boundary includes land-related emissions and removals from bioenergy feedstocks. Long-Term Targets: Merck & Co., Inc., Rahway, New Jersey, U.S.A., which is known as MSD outside the U.S. and Canada commits to reduce absolute scope 1, 2 and 3 GHG emissions 90% by 2045 from a 2019 base year.* *The target boundary includes land-related emissions and removals from bioenergy feedstocks.
Statut
Targets setAnnée cible
2045
Statut
BA1.5 memberDate d'engagement
16/03/2023
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
US58933Y1055
LEI
4YV9Y5M8S0BRK1RP0397
Source : Science Based Targets initiative | Données publiques